Neuroendocrine tumors develop in the cells of the neuroendocrine system, a network of glands throughout the body that produce hormones. Neuroendocrine tumors are rare, typically affecting 1 – 2 people per 100,000 people.
The different types of neuroendocrine tumors depend on the particular cells that are affected. They usually develop in the digestive system and the lungs. Approximately 38% of tumors are in the appendix, 23% in the ileum (also known as carcinoids), 13% in the rectum and 11.5% in the bronchi.
Symptoms of Neuroendocrine tumors
Neuroendocrine tumors may be slow growing (low grade or well differentiated) or rapidly growing (high grade or poorly differentiated). They may be functional (release hormones) or nonfunctional. When functional neuroendocrine tumors release a variety of hormones including a hormone called serotonin, a condition called carcinoid syndrome may occur. Symptoms most commonly associated with neuroendocrine tumors include flushing, diarrhea, weight loss, abdominal pain and cramping. Patients with carcinoid syndrome may also experience cardiac changes, which are caused from fibrotic damage to the heart. Usually a patient with carcinoid syndrome does not experience these symptoms until the tumor has spread within the body.
Other terms used for neuroendocrine tumors include
• Gastroenteropancreatic neuroendocrine tumors – tumors in the gut or pancreas
• Pancreatic neuroendocrine tumors – also known as islet cell cancer, or PNET
• Gastrointestinal neuroendocrine tumors – tumors that develop in the bowel, stomach or esophagus
• Pheochromocytoma of the adrenal gland
• Carcinoid tumors of the lung or intestinal tract
• Carcinoid Syndrome
• Gastrinoma, Insulinoma, Glucagonoma, VIPoma (vasoactive intestinal peptide tumor)
Treatment of neuroendocrine tumors
Treating neuroendocrine tumors can be a challenge due to the various types, locations in the body, the symptoms they produce and the diverse number of treatment modalities. Treatment is individualized to each patient but can include surgery, liver directed therapy, medications, and/or radiation.
When treating a rare, challenging cancer such as neuroendocrine cancer, it is important to have a team of healthcare professionals at your side who are experts in the disease and can collaborate to create a treatment plan individualized to each patient.
At Winship Cancer Institute of Emory University, we take this multidisciplinary approach with teams of expert medical oncologists, surgical oncologists, interventional oncologists, gastroenterologists, pulmonologists, endocrinologists, nurses, and dieticians ( just to name a few) to create a care plan unique to each patient.
About Bonnie Josaphs, RN, BSN, OCN
Ms. Josaphs received her Bachelor of Science in Nursing from the University of Delaware, Newark, Delaware in 2002. She has been practicing within Gastrointestinal (GI) Oncology since 2004. She specializes in gastrointestinal cancers which include cancers of the esophagus, liver, colon, rectum, pancreas, gallbladder and stomach.



The Centers for Disease Control and Prevention (CDC) estimates that more than 2,300 cases of HPV associated head and neck cancers are diagnosed each year in women and more than 9,000 in men. Although alcohol and tobacco continue to be major risk factors for developing cancer of the mouth, throat or voice box, recent studies by the CDC have shown that approximately 63% of cancers associated with the tonsils and base of tongue are associated with HPV. Join Emory Head and Neck Surgical Oncologist, Mark W. El-Deiry, MD FACS on Thursday, January 24 at 12 noon for an online web chat on HPV and Head & Neck Cancer. He will be available to answer questions regarding HPV and Head and Neck Cancer including:









